… cardiovascular events, as compared to a traditional treatment, … antiplatelet therapy or aspirin,
an increased risk of bleeding, 2… clopidogrel and aspirin was superior to aspirin alone in the …

… vascular events prevented in the higher-risk patient … Patients with PAD are at a particularly
high risk of CV events. Guidelines suggests monotherapy (aspirin or clopidogrel) for patients …

… , thus, are at high risk of bleeding. The average age of the … antiplatelet agent was either
aspirin or clopidogrel in the present … Clopidogrel Trial with Irbesartan for prevention of Vascular …

… of aspirin restricted to the presystemic circulation reduced the risk of ischemic heart disease
by … on major bleeding events among 5,085 men, aged 45–69 years, at high risk of ischemic …

… Patients with CAD or peripheral artery disease (PAD) who also have HF have nearly a 2-fold
higher risk of subsequent cardiovascular events than … therapy that typically includes aspirin. …

… cardiovascular event (MACE) outcome of cardiovascular … trial (Clopidogrel for High
Atherothrombotic Risk and Ischemic … alone at 3 months following PCI in patients at high risk for a …

… in the prevention of cardiovascular events after … We aimed to examine the risk of major
cardiovascular events … favor of an increased risk of major cardiovascular events if patients use PPI …

… adverse cardiovascular events (MACE) among clopidogrel … potential increased risk of
adverse cardiovascular events and … or aspirin plasma levels among patients on aspirin/PPI …

… risk of CV disease within 10 years was established to balance the associated increased
risk of bleeding with aspirin … cessation of antiplatelet agents (aspirin, clopidogrel, or both) in …

… that among patients with a high CV risk or patients with established coronary artery disease,
… of care to prevent graft occlusion and MACEs following coronary artery bypass grafting (…